A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma
{{output}}
Background & aims: Patients with metastatic, treatment-refractory, and relapsed hepatoblastoma (HB) have survival rates of less than 50% due to limited treatment options. To develop new therapeutic strategies for these patients, ... ...
